Nat2 - N-acetyltransferase 2 (arylamine N-acetyltransferase) Gene

Species: Mus musculus

Gene Type: protein coding
Gene ID: 17961

Summary

Enables arylamine N-acetyltransferase activity. Predicted to be located in cytosol. Is expressed in several structures, including adrenal gland; female reproductive system; respiratory system; spleen; and sympathetic ganglion. Human ortholog(s) of this gene implicated in several diseases, including autoimmune disease (multiple); carcinoma (multiple); contact dermatitis (multiple); leukemia (multiple); and lung disease (multiple). Orthologous to several human genes including NAT1 (N-acetyltransferase 1). [provided by Alliance of Genome Resources, Apr 2022]

Nat2 Products (2)

mRNA Protein Name
NM_001168577.1 NP_001162049.1 arylamine N-acetyltransferase 2
NM_010874.3 NP_035004.1 arylamine N-acetyltransferase 2

Gene Ontology

  • Molecular Function
Molecular Function GO Annotation Evidence Verweise Source
enables arylamine N-acetyltransferase activity IDA
IDA: Inferred from direct assay
7545952 MGI
enables arylamine N-acetyltransferase activity IMP
IMP: Inferred from mutant phenotype
12815365 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

arylamine N-acetyltransferase 2

  • N-acetyl transferase 2

  • N-acetyltransferase type 2

  • NAT-2

  • arylamide acetylase 2

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Art. -Nr. Produktname Wirkung
Reinheit Rare Diseases
HY-66005 Acetaminophen 99.97% Unkown
HY-66004 4-Acetamidophenyl acetate 97.0% Yes
HY-66004R 4-Acetamidophenyl acetate (Standard) / Unkown

Clinical Phase

Bioactive Molecules (1)
Art. -Nr. Produktname Wirkung
Reinheit Phase
HY-145954 NAT2-IN-1 Inhibitor 99.0% Phase 2

Pre-clinical Phase

Bioactive Molecules (17)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-66005R Acetaminophen (Standard) Inhibitor 99.97% Unkown
HY-66005S Acetaminophen-d4 Inhibitor 99.60% Unkown
HY-113083 Acetaminophen glucuronide 99.96% Unkown
HY-66005S2 Acetaminophen-d7 99.92% Unkown
HY-66005S4 Acetaminophen-13C2,15N 98.30% Unkown
HY-66005S1 Acetaminophen-d3 Inhibitor 99.97% Unkown
HY-121870 Dimethocaine Substrate 99.90% Unkown
HY-135325 4-Hydroxyacetophenone oxime 99.96% Unkown
HY-66005S3 Acetaminophen-13C6 Inhibitor / Unkown
HY-D2983 ARHB / Unkown
HY-RS09042 NAT2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS13217 SLC38A1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-66005S5 Acetaminophen-d5 Inhibitor / Unkown
HY-RS17410 Nat2 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS20218 Slc38a1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23864 Nat2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W713313 3,5-DMA hydrochloride Ligand / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Nat2 NCBI NCBI:10